首页 > 最新文献

Mayo Clinic proceedings. Innovations, quality & outcomes最新文献

英文 中文
Rethinking Measures and Mortality Attribution in Health Care: The Diabetes and Endocrinology Example 重新思考医疗保健中的措施和死亡率归因:糖尿病与内分泌学实例
Pub Date : 2024-09-06 DOI: 10.1016/j.mayocpiqo.2024.08.001
Lorenzo Olivero MD , Jorge Sinclair MD , Trisha Singh MD , Aditya A. Khanijo MBBS , Gunjan Mundhra MBBS , Ana-Maria Chindris MD , Terri Menser PhD , Pablo Moreno Franco MD , Benjamin D. Pollock PhD , Razvan M. Chirila MD

This study investigated the accuracy of mortality attributions assigned by the US News and World Report (USNWR) to the diabetes and endocrinology specialty. We reviewed medical records of all consecutive Medicare fee-for-service inpatients at Mayo Clinic, Florida (Jacksonville, Florida) with a Medicare Severity Diagnosis Related Group included in the USNWR Diabetes & Endocrinology specialty cohort admitted from November 2018 to April 2022, with documented mortality in our institution’s electronic health record within 30 days of the index admission. A clinician adjudicated the primary cause of death, categorizing it as diabetes or endocrine, cancer, failure to thrive, or other. Among 49 deceased patients, only 7 (14.3%) had diabetes or an endocrine-related cause of death. Cancer (49.0%) and failure to thrive (30.6%) were the leading causes. This substantial discrepancy (86% misattribution) suggests USNWR’s methodology might not precisely reflect the quality of care, potentially misleading patients and impacting hospital rankings.

本研究调查了《美国新闻与世界报道》(USNWR)为糖尿病和内分泌专科指定的死亡率归因的准确性。我们查阅了佛罗里达州梅奥诊所(佛罗里达州杰克逊维尔市)所有连续医保付费服务住院患者的病历,这些患者的医保严重程度诊断相关组均包含在《美国新闻与世界报道》糖尿病与amp; 内分泌专科队列中,入院时间为2018年11月至2022年4月,并在索引入院后30天内在本机构的电子病历中记录有死亡病例。临床医生对主要死因进行了判定,将其归类为糖尿病或内分泌、癌症、发育不全或其他。在 49 名死亡患者中,只有 7 人(14.3%)的死因与糖尿病或内分泌有关。癌症(49.0%)和发育不良(30.6%)是主要死因。这一巨大差异(86%的错误归因)表明,USNWR的方法可能无法准确反映医疗质量,从而可能误导患者并影响医院排名。
{"title":"Rethinking Measures and Mortality Attribution in Health Care: The Diabetes and Endocrinology Example","authors":"Lorenzo Olivero MD ,&nbsp;Jorge Sinclair MD ,&nbsp;Trisha Singh MD ,&nbsp;Aditya A. Khanijo MBBS ,&nbsp;Gunjan Mundhra MBBS ,&nbsp;Ana-Maria Chindris MD ,&nbsp;Terri Menser PhD ,&nbsp;Pablo Moreno Franco MD ,&nbsp;Benjamin D. Pollock PhD ,&nbsp;Razvan M. Chirila MD","doi":"10.1016/j.mayocpiqo.2024.08.001","DOIUrl":"10.1016/j.mayocpiqo.2024.08.001","url":null,"abstract":"<div><p>This study investigated the accuracy of mortality attributions assigned by the US News and World Report (USNWR) to the diabetes and endocrinology specialty. We reviewed medical records of all consecutive Medicare fee-for-service inpatients at Mayo Clinic, Florida (Jacksonville, Florida) with a Medicare Severity Diagnosis Related Group included in the USNWR Diabetes &amp; Endocrinology specialty cohort admitted from November 2018 to April 2022, with documented mortality in our institution’s electronic health record within 30 days of the index admission. A clinician adjudicated the primary cause of death, categorizing it as diabetes or endocrine, cancer, failure to thrive, or other. Among 49 deceased patients, only 7 (14.3%) had diabetes or an endocrine-related cause of death. Cancer (49.0%) and failure to thrive (30.6%) were the leading causes. This substantial discrepancy (86% misattribution) suggests USNWR’s methodology might not precisely reflect the quality of care, potentially misleading patients and impacting hospital rankings.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":"8 5","pages":"Pages 475-479"},"PeriodicalIF":0.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000535/pdfft?md5=13e13dc82a20e1c13a4b590ae2b0c6c8&pid=1-s2.0-S2542454824000535-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142151965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lifestyle Medicine in Medical Education: Maximizing Impact 医学教育中的生活方式医学:最大化影响
Pub Date : 2024-08-24 DOI: 10.1016/j.mayocpiqo.2024.07.003
Beth Frates MD, FACLM, DipABLM , Hugo A. Ortega MD, MSEd, DipABLM , Kelly J. Freeman MSN, AGPCNP-BC, DipACLM , John Patrick T. Co MD, MPH, MBA , Melissa Bernstein PhD, RDN, LD, FAND, DipACLM

The relationship between lifestyle behaviors and common chronic conditions is well established. Lifestyle medicine (LM) interventions to modify health behaviors can dramatically improve the health of individuals and populations. There is an urgent need to meaningfully integrate LM into medical curricula horizontally across the medical domains and vertically in each year of school and training. Including LM content in medical and health professional curricula and training programs has been challenging. Barriers to LM integration include lack of awareness and prioritization of LM, limited time in the curricula, and too few LM-trained faculty to teach and role model the practice of LM. This limits the ability of health care professionals to provide effective LM and precludes the wide-reaching benefits of LM from being fully realized. Early innovators developed novel tools and resources aligned with current evidence for introducing LM into didactic and experiential learning. This review aimed to examine the educational efforts in each LM pillar for undergraduate and graduate medical education. A PubMed-based literature review was undertaken using the following search terms: lifestyle medicine, education, medical school, residency, and healthcare professionals. We map the LM competencies to the core competency domains of the Accreditation Council for Graduate Medical Education. We highlight opportunities to train faculty, residents, and students. Moreover, we identify available evidence-based resources. This article serves as a “call to action” to incorporate LM across the spectrum of medical education curricula and training.

生活方式行为与常见慢性病之间的关系已得到公认。改变健康行为的生活方式医学(LM)干预措施可显著改善个人和人群的健康状况。目前迫切需要将生活方式医学有意义地纳入医学课程,横向贯穿医学领域,纵向贯穿学校和培训的每一年。将 LM 内容纳入医学和健康专业课程及培训计划一直是一项挑战。将 LM 纳入课程的障碍包括缺乏对 LM 的认识和优先考虑、课程时间有限、接受过 LM 培训的教师太少,无法教授和示范 LM 的实践。这限制了医护专业人员提供有效 LM 的能力,使 LM 的广泛益处无法充分实现。早期的创新者开发了与当前证据相一致的新型工具和资源,用于将 LM 引入教学和体验式学习中。本综述旨在研究本科生和研究生医学教育中 LM 各支柱的教育工作。我们使用以下检索词进行了基于 PubMed 的文献综述:生活方式医学、教育、医学院、住院医师培训和医疗保健专业人员。我们将生活方式医学的能力与医学研究生教育认证委员会的核心能力领域相匹配。我们强调了培训教师、住院医师和学生的机会。此外,我们还确定了可用的循证资源。本文是将 LM 纳入医学教育课程和培训的 "行动号召"。
{"title":"Lifestyle Medicine in Medical Education: Maximizing Impact","authors":"Beth Frates MD, FACLM, DipABLM ,&nbsp;Hugo A. Ortega MD, MSEd, DipABLM ,&nbsp;Kelly J. Freeman MSN, AGPCNP-BC, DipACLM ,&nbsp;John Patrick T. Co MD, MPH, MBA ,&nbsp;Melissa Bernstein PhD, RDN, LD, FAND, DipACLM","doi":"10.1016/j.mayocpiqo.2024.07.003","DOIUrl":"10.1016/j.mayocpiqo.2024.07.003","url":null,"abstract":"<div><p>The relationship between lifestyle behaviors and common chronic conditions is well established. Lifestyle medicine (LM) interventions to modify health behaviors can dramatically improve the health of individuals and populations. There is an urgent need to meaningfully integrate LM into medical curricula horizontally across the medical domains and vertically in each year of school and training. Including LM content in medical and health professional curricula and training programs has been challenging. Barriers to LM integration include lack of awareness and prioritization of LM, limited time in the curricula, and too few LM-trained faculty to teach and role model the practice of LM. This limits the ability of health care professionals to provide effective LM and precludes the wide-reaching benefits of LM from being fully realized. Early innovators developed novel tools and resources aligned with current evidence for introducing LM into didactic and experiential learning. This review aimed to examine the educational efforts in each LM pillar for undergraduate and graduate medical education. A PubMed-based literature review was undertaken using the following search terms: <em>lifestyle medicine, education, medical school, residency, and healthcare professionals</em>. We map the LM competencies to the core competency domains of the Accreditation Council for Graduate Medical Education. We highlight opportunities to train faculty, residents, and students. Moreover, we identify available evidence-based resources. This article serves as a “call to action” to incorporate LM across the spectrum of medical education curricula and training.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":"8 5","pages":"Pages 451-474"},"PeriodicalIF":0.0,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000444/pdfft?md5=1a959f156528bc6f7c327b8f469a212c&pid=1-s2.0-S2542454824000444-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142050041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Building a Cancer Care Clinic for Transgender and Gender Diverse Individuals 为变性人和性别多元化人士建立癌症护理诊所
Pub Date : 2024-08-22 DOI: 10.1016/j.mayocpiqo.2024.07.007
Elizabeth J. Cathcart-Rake MD , Amye Tevaarwerk MD , Aminah Jatoi MD , Evelyn F. Carroll MD , NFN Scout MA, PhD , Victor G. Chedid MD, MS , Cesar A. Gonzalez PhD , Kelli Fee-Schroeder DNP, RN, OCN , Jewel M. Kling MD, MPH , Chrisandra L. Shufelt MD, MS , Jennifer L. Ridgeway PhD , Caroline Davidge-Pitts MBBCh

Transgender and gender diverse (TGD) people experience disparities in cancer care, including more late-stage diagnoses, worse cancer-related outcomes, and an increased number of unaddressed and more severe symptoms related to cancer and cancer-directed therapy. This article outlines plans to address the unique needs of TGD people through a TGD-focused oncology clinic. Such a clinic could be structured by upholding the following tenets: (1) champion a supportive, gender-affirming environment that seeks to continuously improve, (2) include a transdisciplinary team of specialists who are dedicated to TGD cancer care, and (3) initiate and embrace TGD-patient-centric research on health outcomes and health care delivery.

变性人和性别多元化(TGD)人群在癌症护理方面存在差异,包括更多的晚期诊断、更差的癌症相关预后,以及更多与癌症和癌症导向疗法相关的未处理和更严重的症状。本文概述了通过以 TGD 为重点的肿瘤诊所来满足 TGD 独特需求的计划。这样的诊所可以通过坚持以下原则来构建:(1) 倡导一个支持性的、性别平等的环境,力求不断改进;(2) 包括一个致力于 TGD 癌症治疗的跨学科专家团队;(3) 启动并接受以 TGD 患者为中心的健康结果和医疗服务研究。
{"title":"Building a Cancer Care Clinic for Transgender and Gender Diverse Individuals","authors":"Elizabeth J. Cathcart-Rake MD ,&nbsp;Amye Tevaarwerk MD ,&nbsp;Aminah Jatoi MD ,&nbsp;Evelyn F. Carroll MD ,&nbsp;NFN Scout MA, PhD ,&nbsp;Victor G. Chedid MD, MS ,&nbsp;Cesar A. Gonzalez PhD ,&nbsp;Kelli Fee-Schroeder DNP, RN, OCN ,&nbsp;Jewel M. Kling MD, MPH ,&nbsp;Chrisandra L. Shufelt MD, MS ,&nbsp;Jennifer L. Ridgeway PhD ,&nbsp;Caroline Davidge-Pitts MBBCh","doi":"10.1016/j.mayocpiqo.2024.07.007","DOIUrl":"10.1016/j.mayocpiqo.2024.07.007","url":null,"abstract":"<div><p>Transgender and gender diverse (TGD) people experience disparities in cancer care, including more late-stage diagnoses, worse cancer-related outcomes, and an increased number of unaddressed and more severe symptoms related to cancer and cancer-directed therapy. This article outlines plans to address the unique needs of TGD people through a TGD-focused oncology clinic. Such a clinic could be structured by upholding the following tenets: (1) champion a supportive, gender-affirming environment that seeks to continuously improve, (2) include a transdisciplinary team of specialists who are dedicated to TGD cancer care, and (3) initiate and embrace TGD-patient-centric research on health outcomes and health care delivery.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":"8 5","pages":"Pages 443-450"},"PeriodicalIF":0.0,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000481/pdfft?md5=7e3b48bbfa7e691ca0319b97234056da&pid=1-s2.0-S2542454824000481-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142040888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative Mortality: A Retrospective Cohort Study of 75,446 Noncardiac Surgery Patients 围手术期死亡率:75 446 名非心脏手术患者的回顾性队列研究
Pub Date : 2024-08-21 DOI: 10.1016/j.mayocpiqo.2024.07.002
Gregory A. Nuttall MD , Michael P. Merren MD, MS , Julian Naranjo DO , Erica R. Portner RRT, LRT , Amanda R. Ambrose MD , Charanjit S. Rihal MD

Objective

To evaluate whether major adverse cardiac events (MACE) continue to be a major causative factor for mortality after noncardiac surgery.

Patients and Methods

We performed retrospective study of 75,410 adult noncardiac surgery patients at Mayo Clinic Rochester, between January 1, 2016, and May 4, 2018. Electronic medical records were reviewed and data collected on all deaths within 30 days (n=692 patients) of surgery. The incidence of death due to MACE was calculated.

Results

Postoperative MACE occurred in 150 patients (21.4 events per 10,000 patients; 95% CI, 18.2-25.2 events per 10,000 patients) with most occurring within 3 days of surgery (n=113). Postoperative MACE events were associated with atrial fibrillation with rapid rate response in 25 patients (16.7%), sepsis in 15 patients (10%), and bleeding in 15 patients (10%). There were 12 intraoperative deaths of which 9 were due to exsanguination (75%) and the remaining 3 (25%) due to cardiac arrest. Of the 56 deaths on the first 24 hours after surgery, 7 were due to hemorrhage, 17 due to cardiovascular causes, 20 due to sepsis, and 7 due to neurologic disease. The leading cause of total death over 30 days postoperatively was sepsis (28%), followed by malignancy (27%), cardiovascular disease (12%) neurologic disease (12%), and hemorrhage (5%).

Conclusion

MACE was not the leading cause of death both intraoperatively and postoperatively.

目的评估主要心脏不良事件(MACE)是否仍然是非心脏手术后死亡率的主要致病因素。患者和方法我们对2016年1月1日至2018年5月4日期间罗切斯特梅奥诊所的75,410名成人非心脏手术患者进行了回顾性研究。我们查阅了电子病历,并收集了手术后 30 天内所有死亡患者(692 例)的数据。结果150名患者发生了术后MACE(每万名患者21.4例;95% CI,每万名患者18.2-25.2例),其中大部分发生在术后3天内(n=113)。术后MACE事件与心房颤动有关,25名患者(16.7%)出现快速心率反应,15名患者(10%)出现败血症,15名患者(10%)出现出血。术中死亡人数为12人,其中9人(75%)因失血过多死亡,其余3人(25%)因心脏骤停死亡。术后 24 小时内死亡的 56 人中,7 人死于出血,17 人死于心血管疾病,20 人死于败血症,7 人死于神经系统疾病。术后30天内死亡的主要原因是败血症(28%),其次是恶性肿瘤(27%)、心血管疾病(12%)、神经系统疾病(12%)和出血(5%)。
{"title":"Perioperative Mortality: A Retrospective Cohort Study of 75,446 Noncardiac Surgery Patients","authors":"Gregory A. Nuttall MD ,&nbsp;Michael P. Merren MD, MS ,&nbsp;Julian Naranjo DO ,&nbsp;Erica R. Portner RRT, LRT ,&nbsp;Amanda R. Ambrose MD ,&nbsp;Charanjit S. Rihal MD","doi":"10.1016/j.mayocpiqo.2024.07.002","DOIUrl":"10.1016/j.mayocpiqo.2024.07.002","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate whether major adverse cardiac events (MACE) continue to be a major causative factor for mortality after noncardiac surgery.</p></div><div><h3>Patients and Methods</h3><p>We performed retrospective study of 75,410 adult noncardiac surgery patients at Mayo Clinic Rochester, between January 1, 2016, and May 4, 2018. Electronic medical records were reviewed and data collected on all deaths within 30 days (n=692 patients) of surgery. The incidence of death due to MACE was calculated.</p></div><div><h3>Results</h3><p>Postoperative MACE occurred in 150 patients (21.4 events per 10,000 patients; 95% CI, 18.2-25.2 events per 10,000 patients) with most occurring within 3 days of surgery (n=113). Postoperative MACE events were associated with atrial fibrillation with rapid rate response in 25 patients (16.7%), sepsis in 15 patients (10%), and bleeding in 15 patients (10%). There were 12 intraoperative deaths of which 9 were due to exsanguination (75%) and the remaining 3 (25%) due to cardiac arrest. Of the 56 deaths on the first 24 hours after surgery, 7 were due to hemorrhage, 17 due to cardiovascular causes, 20 due to sepsis, and 7 due to neurologic disease. The leading cause of total death over 30 days postoperatively was sepsis (28%), followed by malignancy (27%), cardiovascular disease (12%) neurologic disease (12%), and hemorrhage (5%).</p></div><div><h3>Conclusion</h3><p>MACE was not the leading cause of death both intraoperatively and postoperatively.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":"8 5","pages":"Pages 435-442"},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000432/pdfft?md5=0098ca40105e5ac2d80dc6de8fa7b7d2&pid=1-s2.0-S2542454824000432-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142040887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Redesigning the Care of Musculoskeletal Conditions With Lifestyle Medicine 用生活方式医学重新设计肌肉骨骼疾病的治疗方法
Pub Date : 2024-08-12 DOI: 10.1016/j.mayocpiqo.2024.07.001
Kristi E. Artz MD , Timothy D. Phillips PT, DPT , Janine M. Moore PT, MS, OCS , Kara E. Tibbe MBA

Value-based health care has been accelerated by alternative payment models and has catalyzed the redesign of care delivery across the nation. Lifestyle medicine (LM) is one of the fastest growing medical specialties and has emerged as a high-value solution for root cause treatment of chronic disease. This review detailed a large integrated health care delivery system’s value transformation efforts in the nonoperative treatment of musculoskeletal (MSK) conditions by placing patient-centric, team-based, lifestyle-focused care at the foundation. With an economic and treatment imperative to reimagine care, recognizing more intervention is not always better, a collaborative approach was designed, which placed functional improvement of the patient at the center. This article described the process of implementing LM into an MSK model of care. The change management process impacted clinical, operational, and benefit plan design to facilitate an integrated care model. A new understanding of patients’ co-occurring physical impairments, medical comorbidities, and behavioral health needs was necessary for clinicians to make the shift from a pathoanatomic, transactional model of care to a biopsychosocial, longitudinal model of care. The authors explored the novel intersection of the implementation of a biopsychosocial model of care using LM principles to achieve greater value for the MSK patient population.

以价值为基础的医疗保健因替代支付模式而加速发展,并推动了全国范围内医疗服务的重新设计。生活方式医学(LM)是发展最快的医学专科之一,已成为从根本上治疗慢性疾病的高价值解决方案。本综述详细介绍了一家大型综合医疗保健服务系统在肌肉骨骼(MSK)疾病的非手术治疗方面进行的价值转型,其方法是将以患者为中心、以团队为基础、以生活方式为重点的护理作为基础。由于经济和治疗方面的原因,必须对护理进行重新规划,认识到更多的干预并不总是更好,因此设计了一种协作方法,将患者的功能改善放在中心位置。本文介绍了将 LM 纳入 MSK 医疗模式的过程。变革管理过程影响了临床、运营和福利计划的设计,促进了综合护理模式的发展。临床医生必须对患者同时存在的身体损伤、医疗合并症和行为健康需求有新的认识,才能从病理解剖学、事务性护理模式转变为生物心理社会学、纵向护理模式。作者探讨了利用 LM 原则实施生物心理社会护理模式的新交叉点,以实现 MSK 患者群体的更大价值。
{"title":"Redesigning the Care of Musculoskeletal Conditions With Lifestyle Medicine","authors":"Kristi E. Artz MD ,&nbsp;Timothy D. Phillips PT, DPT ,&nbsp;Janine M. Moore PT, MS, OCS ,&nbsp;Kara E. Tibbe MBA","doi":"10.1016/j.mayocpiqo.2024.07.001","DOIUrl":"10.1016/j.mayocpiqo.2024.07.001","url":null,"abstract":"<div><p>Value-based health care has been accelerated by alternative payment models and has catalyzed the redesign of care delivery across the nation. Lifestyle medicine (LM) is one of the fastest growing medical specialties and has emerged as a high-value solution for root cause treatment of chronic disease. This review detailed a large integrated health care delivery system’s value transformation efforts in the nonoperative treatment of musculoskeletal (MSK) conditions by placing patient-centric, team-based, lifestyle-focused care at the foundation. With an economic and treatment imperative to reimagine care, recognizing more intervention is not always better, a collaborative approach was designed, which placed functional improvement of the patient at the center. This article described the process of implementing LM into an MSK model of care. The change management process impacted clinical, operational, and benefit plan design to facilitate an integrated care model. A new understanding of patients’ co-occurring physical impairments, medical comorbidities, and behavioral health needs was necessary for clinicians to make the shift from a pathoanatomic, transactional model of care to a biopsychosocial, longitudinal model of care. The authors explored the novel intersection of the implementation of a biopsychosocial model of care using LM principles to achieve greater value for the MSK patient population.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":"8 5","pages":"Pages 418-430"},"PeriodicalIF":0.0,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000420/pdfft?md5=f0fcd09920f1f12c0732340e2c1eed5b&pid=1-s2.0-S2542454824000420-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141979844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pub Date : 2024-08-11 DOI: 10.1016/j.mayocpiqo.2024.07.005
{"title":"","authors":"","doi":"10.1016/j.mayocpiqo.2024.07.005","DOIUrl":"10.1016/j.mayocpiqo.2024.07.005","url":null,"abstract":"","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":"8 5","pages":"Page 416"},"PeriodicalIF":0.0,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000468/pdfft?md5=70625411aa00e73f4226645f66a19f26&pid=1-s2.0-S2542454824000468-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141954017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pub Date : 2024-08-11 DOI: 10.1016/j.mayocpiqo.2024.07.004
{"title":"","authors":"","doi":"10.1016/j.mayocpiqo.2024.07.004","DOIUrl":"10.1016/j.mayocpiqo.2024.07.004","url":null,"abstract":"","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":"8 5","pages":"Page 417"},"PeriodicalIF":0.0,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000456/pdfft?md5=9a758ddb2931642c85b8b6236406719b&pid=1-s2.0-S2542454824000456-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141954018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Donation After Circulatory Death Donor Prognostication: An Emerging Challenge in Heart Transplantation 循环死亡捐献者预后:心脏移植手术面临的新挑战
Pub Date : 2024-08-11 DOI: 10.1016/j.mayocpiqo.2024.07.006
Stephen W. English MD, MBA , Alejandro A. Rabinstein MD , Melissa A. Lyle MD
{"title":"Donation After Circulatory Death Donor Prognostication: An Emerging Challenge in Heart Transplantation","authors":"Stephen W. English MD, MBA ,&nbsp;Alejandro A. Rabinstein MD ,&nbsp;Melissa A. Lyle MD","doi":"10.1016/j.mayocpiqo.2024.07.006","DOIUrl":"10.1016/j.mayocpiqo.2024.07.006","url":null,"abstract":"","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":"8 5","pages":"Pages 431-434"},"PeriodicalIF":0.0,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S254245482400047X/pdfft?md5=87e486c33d4cbaee72dac73d60727771&pid=1-s2.0-S254245482400047X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141954015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pub Date : 2024-08-11 DOI: 10.1016/j.mayocpiqo.2024.06.003
{"title":"","authors":"","doi":"10.1016/j.mayocpiqo.2024.06.003","DOIUrl":"10.1016/j.mayocpiqo.2024.06.003","url":null,"abstract":"","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":"8 5","pages":"Page 415"},"PeriodicalIF":0.0,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000407/pdfft?md5=768b9e700a0f7d98cd4a661c8cf6ca5d&pid=1-s2.0-S2542454824000407-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141954016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving Patient Safety Through Proper Ordering and Administration of Andexanet Alfa 通过正确订购和使用 Andexanet Alfa 改善患者安全
Pub Date : 2024-08-01 DOI: 10.1016/j.mayocpiqo.2024.03.003
Krystof Stanek MD , Mohammad T. Hussain MD , Aaron C. Spaulding PhD , Shalmali Borkar MD, MPH , Marwan E. Shaikh MD

Objective

To evaluate prescribing practices for the anti-Xa reversal agent, andexanet alfa, to identify challenges in ordering and administering this medication, and to offer recommendations to improve patient safety.

Patients and Methods

This retrospective study reviewed all adult patients treated with andexanet alfa (AA) at a single institution between January 1, 2018, and March 31, 2020. We identified ordering and administration benchmarks based on recommendations from previous clinical trials on AA. We then reviewed these medical records to determine compliance with these benchmarks. We also collected data related to thrombotic complications and mortality.

Results

Twenty-two AA dosing sets (loading and infusion dose) were given to 20 patients. Eight (36%) dosing sets met our ordering benchmarks regarding appropriate dose, time since last direct oral anticoagulants, urgency of administration, and documentation. Three (14%) dosing sets met the administrative benchmarks of being started within 30 minutes of the initial order, and 13 (59%) dosing sets had timely infusion of the infusion dose after the loading dose. No dosing set met all our administration benchmarks. There was 1 thrombotic event within 24 hours of the correct AA dose and 1 potential death related to AA.

Conclusion

This study highlights challenges in ordering and administering AA at our institution and brings awareness to potential similar concerns at other institutions. These challenges also identified the need for optimized order sets, a streamlined administration process, and frequent provider education to improve patient safety.

目的:评估抗 Xa 逆转剂安达赛酮α的处方做法,确定在订购和使用这种药物时遇到的挑战,并提出改善患者安全的建议。这项回顾性研究回顾了 2018 年 1 月 1 日至 2020 年 3 月 31 日期间在一家机构接受安达赛酮α(AA)治疗的所有成人患者。我们根据以往 AA 临床试验的建议确定了下单和给药基准。然后,我们审查了这些病历,以确定是否符合这些基准。我们还收集了与血栓并发症和死亡率相关的数据。我们为 20 名患者提供了 22 套 AA 给药方案(负荷剂量和输注剂量)。八套配药方案(36%)符合我们在适当剂量、距上次直接口服抗凝药的时间、给药的紧迫性和文件记录方面的订购基准。三套配药方案(14%)达到了在首次下单后 30 分钟内开始给药的管理基准,13 套配药方案(59%)在负荷剂量后及时输注了输注剂量。没有一组配料符合我们的所有管理基准。在使用正确 AA 剂量 24 小时内发生了 1 起血栓事件,1 例死亡可能与 AA 有关。这项研究凸显了本机构在订购和使用 AA 时面临的挑战,同时也让其他机构意识到可能存在类似的问题。这些挑战也明确了优化医嘱集、简化管理流程和经常对医护人员进行教育以提高患者安全的必要性。
{"title":"Improving Patient Safety Through Proper Ordering and Administration of Andexanet Alfa","authors":"Krystof Stanek MD ,&nbsp;Mohammad T. Hussain MD ,&nbsp;Aaron C. Spaulding PhD ,&nbsp;Shalmali Borkar MD, MPH ,&nbsp;Marwan E. Shaikh MD","doi":"10.1016/j.mayocpiqo.2024.03.003","DOIUrl":"10.1016/j.mayocpiqo.2024.03.003","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate prescribing practices for the anti-Xa reversal agent, andexanet alfa, to identify challenges in ordering and administering this medication, and to offer recommendations to improve patient safety.</p></div><div><h3>Patients and Methods</h3><p>This retrospective study reviewed all adult patients treated with andexanet alfa (AA) at a single institution between January 1, 2018, and March 31, 2020. We identified ordering and administration benchmarks based on recommendations from previous clinical trials on AA. We then reviewed these medical records to determine compliance with these benchmarks. We also collected data related to thrombotic complications and mortality.</p></div><div><h3>Results</h3><p>Twenty-two AA dosing sets (loading and infusion dose) were given to 20 patients. Eight (36%) dosing sets met our ordering benchmarks regarding appropriate dose, time since last direct oral anticoagulants, urgency of administration, and documentation. Three (14%) dosing sets met the administrative benchmarks of being started within 30 minutes of the initial order, and 13 (59%) dosing sets had timely infusion of the infusion dose after the loading dose. No dosing set met all our administration benchmarks. There was 1 thrombotic event within 24 hours of the correct AA dose and 1 potential death related to AA.</p></div><div><h3>Conclusion</h3><p>This study highlights challenges in ordering and administering AA at our institution and brings awareness to potential similar concerns at other institutions. These challenges also identified the need for optimized order sets, a streamlined administration process, and frequent provider education to improve patient safety.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":"8 4","pages":"Pages 407-414"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000134/pdfft?md5=0798b850a649b22639f8402e72ce6e3f&pid=1-s2.0-S2542454824000134-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141946748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Mayo Clinic proceedings. Innovations, quality & outcomes
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1